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Tetrahydrobiopterin (BH4) is an essential cofactor for endothelial nitric oxide (NO) synthase. Guanosine 5 -triphosphate
cyclohydrolase-I (GTPCH-I) is a key limiting enzyme for BH4 synthesis. In the present in vitro study, we investigated whether
peroxisome proliferator-activated receptor α (PPAR-α) agonist fenoﬁbrate could recouple eNOS by reversing low-expression
of intracellular BH4 in endothelial cells and discussed the potential mechanisms. After human umbilical vein endothelial cells
(HUVECs)weretreatedwithlipopolysaccharide(LPS)for24hours,thelevelsofcellulareNOS,BH4andcellsupernatantNOwere
signiﬁcantly reduced compared to control group. And the ﬂuorescence intensity of intracellular ROS was signiﬁcantly increased.
But pretreated with fenoﬁbrate (10umol/L) for 2 hours before cells were induced by LPS, the levels of eNOS, NO, and BH4 were
signiﬁcantlyraisedcomparedtoLPStreatmentalone.ROSproductionwasmarkedlyreducedinfenoﬁbrategroupthanLPSgroup.
In addition, our results showed that the level of intracellular GTPCH-I detected by western blot was increased in a concentration-
dependent manner after being treated with fenoﬁbrate. These results suggested that fenoﬁbrate might help protect endothelial
function and against atherosclerosis by increasing level of BH4 and decreasing production of ROS through upregulating the level
of intracellular GTPCH-I.
1.Introduction
Nitric oxide (NO) is a gas with a half-life of several
seconds. It has a pivotal role in vascular homeostasis, such
as regulating vascular tone and blood pressure inhibiting
platelet aggregation and proliferation of vascular smooth
muscle cells and the expression of inﬂammatory cytokines.
Many studies have established that loss of NO bioavailability
is a key feature of endothelial dysfunction preceding the ap-
pearance of atherosclerosis [1, 2].
Endogenous NO is derived from L-arginine in the catal-
ysis of endothelial NO synthase (NOS), which has binding
sites for tetrahydrobiopterin (BH4), L-arginine, heme, ﬂavin
adenine dinucleotide (FAD), and ﬂavin mononucleotide
(FMN) [3]. BH4 is an essential cofactor for endothelial
NOS (eNOS). It not only stabilizes the structure of eNOS
but also plays a role in the electron transfer during the
production of NO [4, 5]. When BH4 levels are inadequate,
eNOS is no longer coupled to L-arginine oxidation, which
results in reactive oxygen species (ROS) rather than NO2 PPAR Research
production, thereby inducing vascular endothelial dysfunc-
tion [6, 7]. Several studies suggest a possible role for
BH4 in regulating NO-mediated endothelial function. Oral
administration of BH4 can improve endothelial function
in hypercholesterolemia patients, diabetic patients, and
patients with or without coronary artery disease (CAD)
[8–11]. Ozaki et al. showed that chronic overexpression
of eNOS does not inhibit, but accelerates, atherosclerosis
under hypercholesterolemia and that eNOS dysfunction
appears to play important roles in the progression of
atherosclerosis in apoE-deﬁcient/eNOS-overexpressing mice
(apoE-KO/eNOS-Tg mice). But supplementation with BH4
reduced the atherosclerotic lesion size in apoE-KO/eNOS-Tg
mice to the level comparable to apoE-KO mice [12]. Another
study showed that oral administration of BH4 slowed the
progressionofatherosclerosisinapoE-KOmice[13].Guano-
sine 5 -triphosphate cyclohydrolase-I (GTPCH-I), encoded
by the GCH-I gene, is the rate-limiting enzyme in BH4
synthesis. In diabetic GCH-Tg mice, superoxide produc-
tion from endothelium was markedly reduced compared
with that of diabetic mice induced by streptozotocin, and
NO-mediated vasodilatation was preserved [14]. Zheng
et al. [15] found that gene transfer of GTPCH-I could
reverse the BH4 deﬁciency and endothelial dysfunction by
reducing O2
− in low renin mineralocorticoid hyperten-
sion. In addition, exposure of bovine aortic endothelial
cells to GTPCH-I inhibitors or siRNA markedly reduced
BH4 and NO levels but increased superoxide anion levels
[16].
Hypolipidemic ﬁbrates are pharmacological compounds
which activate peroxisome proliferator-activated receptor
α (PPAR-α) ,an u m b e ro ft h en u c l e a rh o r m o n er e c e p t o r
superfamily.ManystudiesshowedthatPPAR-αagonistshave
a lot of beneﬁts on endothelial function independent of
their hypolipidemic eﬀects. Researchers found that PPAR-α
activators play a role in cardiovascular protection through
an increase in eNOS expression level and phosphorylation
of eNOS ser-1179 and NO production in bovine aortic
endothelial cells [17, 18]. Ryan et al. reported that PPAR-
α agonist fenoﬁbrate improves endothelial function and
reduces arterial stiﬀness in obese glucose-tolerant men [19].
Recent evidence indicates that recoupling eNOS may be
a potential approach augmenting the eﬀects of PPAR-α
on eNOS. However, the precise eﬀects of PPARα agonist
on recoupling eNOS and its potential mechanism remain
uncertain.
Our previous study demonstrated that homocysteine
impairs coronary artery endothelial function by decreasing
the level of BH4 in patients with hyperhomocysteinemia
[20]. Our previous study also showed that plasma level
of BH4 was signiﬁcantly increased by PPARα agonist
fenoﬁbrate in patients with hypertriglyceridemia. Moreover,
coronary ﬂow velocity reserve (CFVR) was signiﬁcantly
improved with fenoﬁbrate treatment [21].
Despite PPAR-α activation may have favorable
endothelium-protecting properties, the precious mechanism
on eNOS coupling status remains uncertain. In the present
study, we investigated whether PPAR-α agonist fenoﬁbrate
could improve the expression of intracellular BH4 through
upregulating GTPCH-I, thus contributing to the recoupling
of eNOS.
2.MaterialsandMethods
2.1. Cell Culture. Endothelial cells were isolated from seg-
ments of human umbilical cord vein by collagenase diges-
tion. They were cultured in medium 199 supplemented
with 10% fetal calf serum as previously described [22].
The medium was renewed every 2 days until conﬂuence
(3-4 days); cells were then detached by incubation in PBS
containing 0.05% trypsin and 0.03% EDTA for 1min at
room temperature, washed by centrifugation and reseeded
onto 35, 60, or 100mm plastic culture dishes for ROS,
detection, eNOS, BH4, and GTPCH-I measurement. At early
c o n ﬂ u e n c e ,c e l l sw e r et r e a t e dw i t hL P Si nt h ep r e s e n c eo f
fenoﬁbrate or not as indicated in the ﬁgure legends. Only
endothelial cells passaged less than six times were used for
experiments.
2.2. Measurement of Intracellular BH4. For the measurement
of total biopterin, high-performance liquid chromatogra-
phy (HPLC) was used, as previously described with some
modiﬁcation [23]. Cell lysates were suspended in distilled
water containing 1mM Dithiothreitol, 50mM Tris-HCl (pH
7.4), and 1mM EDTA, centrifuged at 12000g at 4◦Cf o r
15min, and then subjected to oxidation in acid and base.
The supernatant (90ul) was transferred to an amber tube,
and 10uL of 1:1 mixture of 1.5M HClO4 and 2M H3PO4
was added, followed by centrifugation at 13000g for 10min
at 4◦C. The supernatant (90ul) was transferred to a new
amber tuber, and 10uL of iodine solution (1% iodine and
2% KI in 1M HCl solution) was added to the process
of acid oxidation in order to determine total biopterin
(BH4, dihydropterin (BH2), and oxidized biopterin(B)).
After mixing and standing for 60min in the dark at room
temperature, excess iodine was reduced by the addition of
5uL fresh ascorbic acid (20mg/mL in water). To determine
BH2 + B by alkaline oxidation, 10uL of 1M NaOH was
added to 80uL extract, and then 10uL of alkaline iodine
solution (1% iodine and 2% KI in 1M NaOH solution) was
added. After mixing and standing for 60min in the dark
at room temperature, 20uL of 1M H3PO4 was added to
acidify alkaline oxidation, and then 5uL fresh ascorbic acid
(20mg/mL in water) was added to reduce excess iodine.
Samples oxidized under acidic or alkaline conditions were
centrifuged at 13000g for 10min at 4◦C. The supernatant
90uLwasinjectedintothecolumnbyuseofanHPLCsystem
with an autosampler and a ﬂuorescence detector (Agilent
1100). A Hypersil C18 column (4.6mm × 250mm, 5um)
was used for separation of biopterin with a mobile phase of
ration of methanol to water (5:95, v/v) running at a ﬂow
rate of 1.0mL/min. The retention time of biopterin was
approximately 7.5min, and the excitation and emission wave
lengths were 350 and 440nm, respectively. Compounds were
quantitated by their peak height in comparison with external
standards. And BH4 concentrations, expressed as pmol/mg
protein, were calculated by subtracting BH2 + B from total
biopterin.PPAR Research 3
2.3. Measurement of Intracellular eNOS. Level of eNOS was
measured by use of ELISA kits according to the manufac-
turer’s protocols (BioPCR, China).
2.4. Measurement of Cell Supernatant NO. NO level was
measured by use of an ELISA kit according to the manufac-
turer’s protocols (Jiamay Biotech, China).
2.5. Measurement of Intracelluar ROS Generation. Determi-
nation of intracellular oxidant production in endothelial
cells was based on the oxidation of an ROS probe dye
2 ,7 -dichloroﬂuorescin diacetate (DCF-DA, 20umol/L) by
intracellular ROS, and resulting in the formation of the ﬂuo-
rescentcompound2 ,7 -dichloroﬂuorescin(DCF).AndDCF
ﬂorescence was monitored with a confocal laser scanning
microscope (Leica) [24].
2.6. Western Blot Analysis. HUVECs were lysated with cell-
lysis buﬀer (150mM NaCl, 100mM Tris-HCl pH 7.4, 1mM
Na2 EDTA,1%Triton-X,10ug/mLaprotinin,10ug/mLpep-
statin A, 10ug/mL leupeptin, 0.05M NaF, 0.01M Na4O7P2,
1M N a 3VO4) and 1mM PMSF. The protein content was
assayed by BCA protein assay reagent. 40ug protein were
loaded to SDS-PAGE and then transferred to PVDF mem-
branes. After incubation for 1 hour in blocking buﬀer (5%
skimmilkpowderinTBS-T),themembraneswereincubated
with primary antibody (Santa Cruz, USA) with a 1:1000
dilution, followed by incubating with ﬂuorescently labeled
secondary antibody (Invitrogen, USA). Protein bands were
visualizedbyOdysseyinfraredimagingsystem(LI-CORBio-
sciences,USA),andtheintensityofeachbandswasmeasured
by the accompanied software. We used control as 100%.
2.7. Statistical Analysis. Dates were reported as means ± SD.
The diﬀerences between groups were analyzed by one-way
ANOVA,andP<0.05wasconsideredstatisticallysigniﬁcant.
3. Results
3.1. Eﬀects of Fenoﬁbrate on Intracellular eNOS and Cell
Supernatant NO. As shown in Figure 1, fenoﬁbrate treat-
ment for 24 hours increased the expression of eNOS
protein in a concentration-dependent manner. However,
after HUVECs were treated with LPS for 24 hours, the levels
of cellular eNOS and cell supernatant NO were signiﬁcantly
reduced by 14.4%, 19.9% (both P<0.05) compared to
control groups, respectively. But pretreated with fenoﬁbrate
(10umol/L) for 2 hours before cells were induced by LPS,
the levels of eNOS and NO were signiﬁcantly raised com-
pared to LPS treatment (both P<0.05). We also found that
PPARα blocker GW6471 (10umol/L) abolished the eﬀect
of fenoﬁbrate and PPARα agonist WY14643 (50umol/L)
could produce a similar eﬀect of fenoﬁbrate on intracellular
eNOS and cell supernatant NO. And there was no signiﬁcant
diﬀerence between group of WY14643+LPS and group of
fenoﬁbrate+LPS in the levels of eNOS and NO (P = 0.93,
P = 0.12, resp.).
3.2. Eﬀect of Fenoﬁbrate on Intracellular Level of ROS. As

































































































































































































































































































Figure 1: Eﬀect of fenoﬁbrate and related compounds on levels of
eNOS (a, b) and NO (c) in control group, LPS group, fenoﬁbrate
pretreated group, PPARα antagonist, and agonist group. eNOS and
NO were measured by ELISA kits according to the manufacturer’s
protocols. Values are expressed as means ± SD. (a) ∗P<0.05 versus






























































































Figure 2: Eﬀect of fenoﬁbrate and related compounds on ROS formation in cultured endothelial cells. DCFH-DA (20umol/L) was
added to monitor intracellular ROS production with a confocal laser scanning microscope (Leica). (a) Control group; (b) LPS group; (c)
fenoﬁbrate+LPS; (d) GW6471+fenoﬁbrate+LPS; (e) WY14643+LPS; (f) statistical graph. Values are expressed as means ± SD; n = 6.
∗P<0.05; #P<0.05 versus LPS group.PPAR Research 5
ROS was stronger in LPS group. However, if cells were
pretreated with fenoﬁbrate for 2 hours before being incu-
bated with LPS for 24 hours, ROS ﬂuorescence intensity was
signiﬁcantly reduced in fenoﬁbrate group than LPS group.
In addition, the ﬂuorescence intensity was stronger than
fenoﬁbrate group after being treated by PPARα antagonist
GW6471 (10umol/L). We also found that PPARα agonist
WY14643 (50umol/L) could reduce the level of intracellular
ROS similarly to the eﬀect of fenoﬁbrate. And there was no
signiﬁcant diﬀerence between group of WY14643+LPS and
group of fenoﬁbrate+LPS in the level of ROS (P = 0.25).
3.3. Eﬀe c to fF e n o ﬁ b r a t eo nI n t r a c e l l u l a rL e v e lo fB H 4 .
BH4 is an essential cofactor for eNOS. When BH4 levels
are inadequate, eNOS is no longer coupled to L-arginine
oxidation, which results in ROS rather than NO production.
From above statements we knew that LPS stimulation could
cause more production of ROS in HUVECs, so we next
investigated whether the action of LPS was from the pathway
of BH4. As shown in Figure 3, intracellular BH4 level was
signiﬁcantly lower in LPS group than control group (P<
0.05). However, pretreated with fenoﬁbrate (10umol/L) for
2 hours, intracellular BH4 level was signiﬁcantly higher than
LPS group (P<0.05). PPARα blocker GW6471 (10umol/L)
abolished the eﬀect of fenoﬁbrate on intracellular BH4.
And PPARα agonist WY14643 (50umol/L) could upregulate
the level of intracellular BH4 similarly to fenoﬁbrate without
signiﬁcant diﬀerence (P = 0.25).
3.4. Eﬀect of Fenoﬁbrate on Intracellular Level of GTPCH-
I. GTPCH-I is the rate-limiting enzyme in BH4 synthesis.
We next investigated whether fenoﬁbrate promoted the ex-
pression of BH4 through increasing the level of GTPCH-I
in HUVECs. As shown in Figure 4, fenoﬁbrate treatment for
24 hours increased GTPCH-I expression in a concentration-
dependent manner. The level of GTPCH-I after fenoﬁbrate
treatmentreachedmaximumat12hoursandmaintainedata
high level for a long time. We also found that PPARα blocker
GW6471 (10umol/L) abolished the eﬀect of fenoﬁbrate
and PPARα agonist WY14643 (50umol/L) could produce a
similar eﬀect of fenoﬁbrate on intracellular GTPCH-I. And
there was no signiﬁcant diﬀerence between WY14643 group
and fenoﬁbrate group in the expression of GTPCH-I (P =
0.81).
4. Discussion
BH4 is an essential cofactor for eNOS which catalyzes L-
arginine to L-citrulline with the production of NO, one of
the most important vasodilators. Our study demonstrated
that endothelial cellular eNOS and NO were signiﬁcantly
reduced when incubated with LPS, accompanied by more
ROSproductionandlowerlevelofBH4.However,whenpre-
treatedwithfenoﬁbratebeforeexposingtoLPS,cellularlevels
of eNOS, NO, and BH4 were all signiﬁcantly higher than LPS
group. There was lower level of ROS in the fenoﬁbrate group
thanLPSgroup.Fenoﬁbratetreatmentfor24hoursincreased
GTPCH-I expression in a concentration-dependent manner.
Finally, PPARα antagonist GW6471 could abolish the eﬀects

































































































Figure 3: Eﬀect of fenoﬁbrate and related compounds on intra-
cellular level of BH4 in each group, measured by HPLC. Values
are expressed as means ± SD. BH4: tetrahydrobiopterin. n = 5.
∗P<0.05; #P<0.05 versus LPS group.
WY14643 could produce the similar eﬀect of fenoﬁbrate.
Thus, fenoﬁbrate may help protect endothelial function by
promoting level of BH4 and decreasing production of ROS
through increasing the level of intracellular GTPCH-I.
Endothelial-derived NO is essential in the maintenance
of vascular homeostasis. It has many biological eﬀects,
suchassuppressingplateletaggregation,leukocytemigration
and celluar adhesion to the endothelium, and inhibit-
ing inﬂammatory response and vascular smooth muscle
cell proliferation. Hence, NO is an anti-atherosclerotic
molecule. So loss of NO bioavailability is a key feature of
endothelial feature of endothelial dysfunction preceding the
appearance of atherosclerosis [1, 25]. Hypolipidemic ﬁbrates
are pharmacological compounds which activate PPAR-α,
a number of the nuclear hormone receptor superfamily.
Many studies showed that PPAR-α agonists have a lot of
beneﬁts on vascular endothelial function independent of
their hypolipidemic eﬀects. Researchers found that PPAR-α
activators play a role in cardiovascular protection through
an increase in eNOS expression level and phosphorylation
of eNOS ser-1179 and NO production in Bovine aortic
endothelial cells [17, 18]. In our present study, we showed
that fenoﬁbrate improved the levels of eNOS and NO in
endothelial cells. Tetrahydrobiopterin (BH4) is an essential
cofactor that maintains the normal function of eNOS. When
BH4 level is inadequate, it could transform eNOS into
an oxidant production of ROS. BH4 may improve NO-
mediated endothelial function, thereby potentially reducing
the development of atherosclerosis. Several studies showed
that oral administration of BH4 can improve endothelial






















































































































































































































































Figure 4: Fenoﬁbrate increases GTPCH-I protein levels in HUVECs, as demonstrated by Western blot analyses. (a) Cells were treated for
24h with increasing concentrations of fenoﬁbrate. (b) The level of GTPCH-I after fenoﬁbrate treatment reached maximum at 12 hours
and maintained a high level for a long time. (c) GW6471 antagonizes fenoﬁbrate-induced increase in GTPCH-I protein level, WY14643
increases GTPCH-I protein level similarly to the eﬀect of fenoﬁbrate. Dates are means ± SD in three experiments. (a, b): ∗P<0.05 versus
control group; (c) ∗P<0.05, #P<0.05 versus control group. (d) Proposed scheme: Fenoﬁbrate not only promotes the expression of eNOS,
but also up-regulates the level of GTPCH-I, contributing to the increase of BH4, which could promote the activity of eNOS, thus resulting
the increase of NO and decrease of ROS.PPAR Research 7
and patients with or without coronary artery disease (CAD)
[8–11]. Then, correction of endothelial dysfunction may
explain in part the beneﬁcial eﬀect of PPAR-α agonist
treatment. Our previous study demonstrated that PPAR-α
agonist fenoﬁbrate increased the plasma levels of BH4 and
NO in patients with hypertriglyceridemia [21]. Moreover,
homocysteine impairs coronary artery endothelial function
by inhibiting tetrahydrobiopterin in patients with hyperho-
mocysteinemia [20]. We hypothesized that fenoﬁbrate could
promote the activity of eNOS through restoring the level
of BH4 contributing to lower level of ROS. As mentioned
earlier, when treated with fenoﬁbrate, the intracellular
level of BH4 was signiﬁcantly improved compared to LPS
treatment alone, accompanied by lower ROS generation.
These results suggest that fenoﬁbrate might have potentially
beneﬁcial eﬀects in endothelial function by promoting the
level of BH4.
Next, GTPCH-I is the rate-limiting enzyme in BH4
synthesis.InmanygenetransferanimalmodelsofGTPCH-I,
such as diabetic GCH-Tg mice and DOCA-salt hypertension
rat, overexpression of GTPCH-I could reverse the BH4
deﬁciency and endothelial dysfunction by reducing superox-
ide anion production and NO-mediated vasodilatation was
preserved [14, 15]. Wang et al. [16] found that exposure
of bovine aortic endothelial cells to GTPCH-I inhibitors or
siRNA markedly reduced BH4 and NO levels but increased
superoxide levels. Some drugs such as statin and metformin
can improve endothelial function through increasing level
of BH4 by diﬀerent mechanisms, such as increasing the
level of GTP cyclohydrolase I (GTPCH I), suppressing 26s
proteasome-mediated GTPCH I degradation to increase the
levelofBH4,andsoon[26–28].Inoursystem,wediscovered
that fenoﬁbrate treatment increased GTPCH-I expression in
a concentration-dependent manner. Then, fenoﬁbrate might
play its endothelial protecting and antiatherosclerosis eﬀect
by up-regulating BH4 and GTPCH-I levels in HUVECs,
which could provide a new perspective for the therapy of
endothelial dysfunction (Figure 4(d)). However, the precise
mechanism of this process needs to be further investigated.
In conclusion, fenoﬁbrate contributes beneﬁcial eﬀect
to prevent endothelial dysfunction from upregulating level
of BH4 and decreasing production of ROS through the
mechanism of increasing the level of intracellular GTPCH-I.
Fenoﬁbrate may help protect against atherosclerosis poten-
tial by promoting the re-coupling of eNOS with normalizing
endothelial disorders.
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